Holen Sie sich die Stockscreener-App
0.695
7.82%
-0.059
Handel nachbörslich:
.73
0.035
+5.04%
Schlusskurs vom Vortag:
$0.754
Offen:
$0.7612
24-Stunden-Volumen:
34,305
Relative Volume:
0.98
Marktkapitalisierung:
$27.80M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-24.77M
KGV:
-0.9026
EPS:
-0.77
Netto-Cashflow:
$-17.36M
1W Leistung:
-7.33%
1M Leistung:
+1.76%
6M Leistung:
-31.19%
1J Leistung:
-32.52%
1-Tages-Spanne:
$0.692
$0.7612
1-Wochen-Bereich:
$0.69
$0.80
52-Wochen-Spanne:
$0.57
$1.90
Mink Therapeutics Inc Stock (INKT) Company Profile
Firmenname
Mink Therapeutics Inc
Sektor
Branche
Telefon
212-994-8250
Adresse
149 FIFTH AVENUE, NEW YORK
Vergleichen Sie INKT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| INKT | 0.695 | 27.80M | 0 | -24.77M | -17.36M | -0.77 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Mink Therapeutics Inc Aktie (INKT) Neueste Nachrichten
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q3 2024 Earnings Call Transcript - Insider Monkey
MiNK Therapeutics Inc (INKT) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
MiNK Therapeutics Reports Q3 Growth and Strategic Advances - TipRanks
MiNK Therapeutics Inc (INKT) Quarterly 10-Q Report - Quartzy
Agenus (AGEN) Stock Dips Amid Financial Performance and Industry Trends - GuruFocus.com
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update - GlobeNewswire
MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report - GlobeNewswire
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
MiNK Therapeutics Sets Q3 2024 Earnings Call: iNKT Cell Therapy Updates Ahead | INKT Stock News - StockTitan
Hedge funds pile into banks, dump green energy post US election, Goldman Sachs says - Yahoo Canada Finance
MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024 - GlobeNewswire
MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid - The Bakersfield Californian
AGENAgenus Inc. Latest Stock News & Market Updates - StockTitan
Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update - Business Wire
MiNK Therapeutics Appoints Dr. Robert Kadlec to Board - TipRanks
Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024 - The Manila Times
MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors - GlobeNewswire
Small Cell Lung Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
BBerg Commodity Index (AHH20) Quote - The Globe and Mail
TSX Industrials Capped Index (TTIN) QuotePress Release - The Globe and Mail
Altria Group (MO-N) QuotePress Release - The Globe and Mail
TSX 60 Equal Weight Index (TXEW) QuotePress Release - The Globe and Mail
TSX Energy Capped Index (TTEN) QuotePress Release - The Globe and Mail
Refractory Multiple Myeloma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Realty Income Corp (O-N) QuotePress Release - The Globe and Mail
TSX Global Base Metals Index (TXBM) QuotePress Release - The Globe and Mail
Nasdaq Biotechnology Index (NBI) QuotePress Release - The Globe and Mail
Alphabet Cl C (GOOG-Q) QuotePress Release - The Globe and Mail
Refractory Multiple Myeloma Pipeline Therapeutics, - openPR
Vertiv Holdings Llc. (VRT-N) QuotePress Release - The Globe and Mail
S&P 500 Information Technology [Sector] (SRIT) QuotePress Release - The Globe and Mail
Meta Platforms Inc (META-Q) QuotePress Release - The Globe and Mail
CAR-T Cell Therapy Competitive Landscape 2024 (Updated) - openPR
MiNK Therapeutics announces executive transition By Investing.com - Investing.com Australia
MiNK Therapeutics announces executive transition - Investing.com India
Renaissance Technologies LLC Makes New Investment in Team, Inc. (NYSE:TISI) - Defense World
Rx Rundown: AstraZeneca, Danco Laboratories, GSK and more - MM+M Online
Poseida Therapeutics’ Allogeneic CAR-T P-BCMA-ALLO1 Demonstrates 91% ORR in Enhanced Lymphodepletion Arm of R/R MM Study - CGTLive™
MiNK Therapeutics Inc (INKT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Around the Helix: Cell and Gene Therapy Company Updates – October 9, 2024 - CGTLive™
MiNK Therapeutics stock gets boost from new RNA collaboration with Autonomous - Investing.com Canada
Mink Therapeutics and Autonomous Therapeutics target metastatic tumors through new collaboration - BioWorld Online
Investor’s Toolkit: Key Ratios for Assessing MiNK Therapeutics Inc (INKT)’s Performance - The Dwinnex
MiNK Therapeutics, Autonomous Therapeutics enter research collaboration - TipRanks
ZenaTech's ZenaDrone Commences Aerial Operations to Commercialize Drone Services in the US Following FAA Approval - The Manila Times
MiNK Therapeutics and Autonomous Therapeutics Announce - GlobeNewswire
MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors - Yahoo Finance
Mink Therapeutics stock hits 52-week low at $0.71 amid market challenges - Investing.com
Finanzdaten der Mink Therapeutics Inc-Aktie (INKT)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):